Oblique Therapeutics
  • Home Page
  • About us
    • Overview
    • Organization
  • Technology
    • AbiprotTM-antibody platform
    • Abiprot SelectTM
  • Portfolio
    • Overview
    • OT-1096 in TNBC
    • aTRPV1 & aTRPA1 in pain
    • aKRAS in colorectal cancer
    • Collaborations in type 2 diabetes
  • Corporate Gouvernance
    • General annual meetings
    • Board of Directors and Management
  • Investors Relations
    • Reports
  • News
    • Press Releases
    • Publications, conferences & press
  • Contact
Oblique Therapeutics > Investors Relations > Press Releases
  • Home Page
  • About us
    • Overview
    • Organization
  • Technology
    • AbiprotTM-antibody platform
    • Abiprot SelectTM
  • Portfolio
    • Overview
    • OT-1096 in TNBC
    • aTRPV1 & aTRPA1 in pain
    • aKRAS in colorectal cancer
    • Collaborations in type 2 diabetes
  • Corporate Gouvernance
    • General annual meetings
    • Board of Directors and Management
  • Investors Relations
    • Reports
  • News
    • Press Releases
    • Publications, conferences & press
  • Contact

2020

Oblique Therapeutics AB raises 98 MSEK in a private placement investment round

Oblique Therapeutics Sahlgrenska University Hospital Karolina Institutet Vinnova

Oblique Therapeutics and Targovax enter collaboration to target mutant RAS

Göteborgsbaserade Oblique Therapeutics AB har gjort potentiellt viktiga upptäckter för antikroppsutveckling mot Covid

Oblique Therapeutics AB has identified a potentially important epitope for generation of SARS-CoV-2 antibodies

2019

Oblique Therapeutics will be presenting at the Inaugural RAS- Targeted Drug Discovery Europe Summit in Vienna in February 2020

Oblique Therapeutics has been recognized as one of the 15 most promising Biotech startups in Europe 2019, by StartUp City magazine

2018

Science Translational Medicine publishes research results from Oblique Therapeutics and Karolinska Institute on a new treatment

Oblique Therapeutics present tumor growth inhibition and Treglowering data for OT1096 congress ESMO

Oblique Therapeutics

Copyright © 2021 Oblique Therapeutics AB.

Contact

Oblique Therapeutics AB
info@obliquet.com

Gothenburg
Arvid Wallgrens Backe 20
413 46 Göteborg
Sweden

Stockholm
Döbelnsgatan 64
113 52 Stockholm
Sweden

Menu
  • Home Page
  • About us
    • Overview
    • Organization
  • Technology
    • AbiprotTM-antibody platform
    • Abiprot SelectTM
  • Portfolio
    • Overview
    • OT-1096 in TNBC
    • aTRPV1 & aTRPA1 in pain
    • aKRAS in colorectal cancer
    • Collaborations in type 2 diabetes
  • Corporate Gouvernance
    • General annual meetings
    • Board of Directors and Management
  • Investors Relations
    • Reports
  • News
    • Press Releases
    • Publications, conferences & press
  • Contact
About

Oblique Therapeutics is a privately held Swedish biotech developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain, and advanced cancer.  The company uses AbiprotTM, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. 

Till toppen

We use cookies to improve the user experience on Oblique Therapeutics. Read more about Cookies

Approve